Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
21 Abril 2023 - 9:30AM
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, announced today that John
Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc
Medicine, will participate in a fireside chat at the H.C.
Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023
at 2:30 p.m. ET.
A live webcast of the fireside chat will be
available through the investor relations section of the Company's
website at ir.discmedicine.com and an archived replay will be
available after the event.
About Disc
Disc Medicine is a clinical-stage biopharmaceutical
company committed to discovering, developing, and commercializing
novel treatments for patients who suffer from serious hematologic
diseases. We are building a portfolio of innovative, potentially
first-in-class therapeutic candidates that aim to address a wide
spectrum of hematologic diseases by targeting fundamental
biological pathways of red blood cell biology, specifically heme
biosynthesis and iron homeostasis. For more information, please
visit www.discmedicine.com.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Suzanne Messere Stern Investor
Relationssuzanne.messere@sternir.com
Disc Medicine (NASDAQ:IRON)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Disc Medicine (NASDAQ:IRON)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024